

**AMENDMENTS TO THE CLAIMS**

1-92. (Canceled)

93. (Currently amended) A composition comprising:

a mixture comprising a first component that comprises an unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments obtained from a patient subject mixed with a second component comprising a concentrated population of cells that comprises adipose-derived stem cells, wherein said concentrated population of cells that comprises adipose-derived stem cells is obtained from said patient subject.

94. (Previously presented) The composition of Claim 93, wherein the amount of adipose-derived stem cells in said first component is less than the amount of adipose-derived stem cells in said second component.

95. (Previously presented) The composition of Claim 93, wherein the amount of adipose-derived stem cells in said second component is at least 0.1% of the total population of cells.

96. (Previously presented) The composition of Claim 93, wherein the amount of adipose-derived stem cells in said second component is between about 2% and about 12% of the total population of cells.

97. (Previously presented) The composition of Claim 93, wherein the volume of the first component is at least 25% greater than the volume of the second component.

98. (Previously presented) The composition of Claim 93, wherein the volume of the first component is at least 50% greater than the volume of the second component.

99. (Previously presented) The composition of Claim 93, wherein the volume of the first component is at least 100% greater than the volume of the second component.

100. (Previously presented) The composition of Claim 93, wherein the volume of the first component is at least 150% greater than the volume of the second component.

101. (Previously presented) The composition of Claim 93, wherein said second component is cryopreserved material.

102. (Previously presented) The composition of Claim 93, wherein said first component is cryopreserved material.

103. (Previously presented) The composition of Claim 93, wherein said second component is substantially free from mature adipocytes and connective tissue.

104. (Currently amended) A composition obtained by a process comprising:  
providing unprocessed adipose tissue from a patientsubject, wherein said unprocessed adipose tissue has not undergone a process to remove cells from said adipose tissue; and wherein said unprocessed adipose tissue comprises intact, non-disaggregated tissue fragments; and

mixing said adipose tissue with a concentrated cell population that comprises adipose-derived stem cells, wherein said concentrated cell population that comprises adipose-derived stem cells is obtained from said patientsubject and said concentrated cell population that comprises adipose-derived stem cells has a concentration of adipose-derived stem cells that is greater than the concentration of adipose-derived stem cells present in said adipose tissue.

105. (Currently amended) The composition of Claim 104, wherein the amount of adipose-derived stem cells in said unprocessed adipose tissue is less than the amount of adipose-derived stem cells in said concentrated cell population that comprises adipose-derived stem cells.

106. (Previously presented) The composition of Claim 104, wherein the amount of adipose-derived stem cells in said concentrated cell population that comprises adipose-derived stem cells is at least 0.1% of the total population of cells.

107. (Previously presented) The composition of Claim 104, wherein the amount of adipose-derived stem cells in said concentrated cell population that comprises adipose-derived stem cells is between about 2% and about 12% of the total population of cells.

108. (Previously presented) The composition of Claim 104, wherein the volume of the adipose tissue is at least 25% greater than the volume of the concentrated cell population that comprises adipose-derived stem cells.

109. (Previously presented) The composition of Claim 104, wherein the volume of the adipose tissue is at least 50% greater than the volume of the concentrated cell population that comprises adipose-derived stem cells.

110. (Previously presented) The composition of Claim 104, wherein the volume of the adipose tissue is at least 100% greater than the volume of the concentrated cell population that comprises adipose-derived stem cells.

111. (Previously presented) The composition of Claim 104, wherein the volume of the adipose tissue is at least 150% greater than the volume of the concentrated cell population that comprises adipose-derived stem cells.

112. (Previously presented) The composition of Claim 104, wherein said concentrated cell population that comprises adipose-derived stem cells is cryopreserved material.

113. (Currently amended) The composition of Claim 104, wherein said unprocessed adipose tissue is cryopreserved material.

114. (Previously presented) The composition of Claim 104, wherein said concentrated cell population that comprises adipose-derived stem cells is substantially free from mature adipocytes and connective tissue.

115. (Currently amended) A composition comprising a mixture of a concentrated population of cells that comprises adipose-derived stem cells and unprocessed adipose tissue comprising intact, non disaggregated tissue fragments of a patient subject obtained by a process comprising:

removing a first portion of adipose tissue that comprises a cell population that comprises adipose-derived stem cells from a patient subject;

introducing said first portion of adipose tissue that comprises said cell population that comprises adipose-derived stem cells into a self-contained adipose-derived stem cell processing unit ~~configured to maintain a closed pathway~~, wherein said self-contained adipose-derived stem cell processing unit comprises:

a tissue collection container that is configured to receive unprocessed adipose tissue that is removed from a subject, wherein said tissue collection container is defined by a closed system;

a first filter that is disposed within said tissue collection container, which wherein said first filter is configured to retain a first component of said unprocessed adipose tissue and pass a second component of said unprocessed adipose tissue, such that said first filter separates said first component from said second component, and wherein said first component comprises a cell population that comprises adipose-derived stem cells and said second component comprises adipose tissue and pass lipid, blood, mature adipocytes and saline;

a cell collection container, which is configured to receive and concentrate said first component comprising a cell population of cells that comprises adipose-derived stem cells from said tissue collection container, wherein said cell collection container is within said closed system; and

a conduit configured to allow passage of said first component comprising a cell population comprising adipose-derived stem cells from said tissue collection container to said cell collection container while maintaining a closed system;

a cell concentrator disposed within said cell collection container that is configured to facilitate the concentration of said first component comprising a cell population that comprises adipose-derived stem cells, wherein said cell concentrator comprises a centrifuge or a spinning membrane filter; and

an outlet configured to allow the aseptic removal of said concentrated population of cells that comprises adipose-derived stem cells;

separating and concentrating said a-cell population that comprises adipose-derived stem cells from the adipocytes and connective tissue present in the said first portion of adipose tissue that was removed from said patient within said self-contained adipose-derived stem cell processing unit while maintaining said closed pathway to obtain a concentrated cell population that comprises adipose-derived stem cells;

concentrating said cell population that comprises adipose-derived stem cells within said self-contained cell processing unit while maintaining said closed pathway;

removing a second portion of adipose tissue from said patient; and

adding to said mixing said concentrated cell population that comprises adipose-derived stem cells with said a second portion of unprocessed adipose tissue comprising intact, non disaggregated tissue fragments from said subject, so as to obtain a mixture of the unprocessed adipose tissue and the concentrated cell population that comprises adipose-derived stem cells obtained from said patient.

116. (Currently amended) The composition of Claim 115, wherein the amount of adipose-derived stem cells in said second portion of unprocessed adipose tissue obtained from

said patientsubject is less than the amount of adipose-derived stem cells in said concentrated cell population that comprises adipose-derived stem cells.

117. (Previously presented) The composition of Claim 115, wherein the amount of adipose-derived stem cells in said concentrated cell population that comprises adipose-derived stem cells is at least 0.1% of the total population of cells.

118. (Previously presented) The composition of Claim 115, wherein the amount of adipose-derived stem cells in said concentrated cell population that comprises adipose-derived stem cells is between about 2% and about 12% of the total population of cells.

119. (Currently amended) The composition of Claim 115, wherein the volume of the second portion of adipose tissue obtained from said patientsubject is at least 25% greater than the volume of the concentrated cell population that comprises adipose-derived stem cells.

120. (Currently amended) The composition of Claim 115, wherein the volume of the second portion of adipose tissue obtained from said patientsubject is at least 50% greater than the volume of the concentrated cell population that comprises adipose-derived stem cells.

121. (Currently amended) The composition of Claim 115, wherein the volume of the second portion of adipose tissue obtained from said patientsubject is at least 100% greater than the volume of the concentrated cell population that comprises adipose-derived stem cells.

122. (Currently amended) The composition of Claim 115, wherein the volume of the second portion of adipose tissue obtained from said patientsubject is at least 150% greater than the volume of the concentrated cell population that comprises adipose-derived stem cells.

123. (Previously presented) The composition of Claim 115, wherein said concentrated cell population that comprises adipose-derived stem cells is cryopreserved material.

124. (Currently amended) The composition of Claim 115, wherein said second portion of adipose tissue obtained from said patientsubject is cryopreserved material.

125. (Previously presented) The composition of Claim 115, wherein said concentrated cell population that comprises adipose-derived stem cells is substantially free from mature adipocytes and connective tissue.